| pubmed-article:14753732 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:14753732 | lifeskim:mentions | umls-concept:C0016658 | lld:lifeskim |
| pubmed-article:14753732 | lifeskim:mentions | umls-concept:C0029456 | lld:lifeskim |
| pubmed-article:14753732 | lifeskim:mentions | umls-concept:C0035647 | lld:lifeskim |
| pubmed-article:14753732 | lifeskim:mentions | umls-concept:C0005938 | lld:lifeskim |
| pubmed-article:14753732 | lifeskim:mentions | umls-concept:C0001645 | lld:lifeskim |
| pubmed-article:14753732 | lifeskim:mentions | umls-concept:C0392756 | lld:lifeskim |
| pubmed-article:14753732 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:14753732 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:14753732 | pubmed:dateCreated | 2004-2-2 | lld:pubmed |
| pubmed-article:14753732 | pubmed:abstractText | This population-based study documented beta-blocker use in 59/569 cases with incident fracture and 112/775 controls. OR for fracture associated with beta-blocker use was 0.68 (95%CI, 0.49-0.96). Beta-blockers were associated with higher BMD at the total hip (2.5%) and UD forearm (3.6%) after adjusting for age, anthropometry, and thiazide use. Beta-blocker use is associated with reduced fracture risk and higher BMD. | lld:pubmed |
| pubmed-article:14753732 | pubmed:language | eng | lld:pubmed |
| pubmed-article:14753732 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14753732 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:14753732 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14753732 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:14753732 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:14753732 | pubmed:issn | 0884-0431 | lld:pubmed |
| pubmed-article:14753732 | pubmed:author | pubmed-author:Geelong... | lld:pubmed |
| pubmed-article:14753732 | pubmed:author | pubmed-author:NicholsonGeof... | lld:pubmed |
| pubmed-article:14753732 | pubmed:author | pubmed-author:PascoJulie... | lld:pubmed |
| pubmed-article:14753732 | pubmed:author | pubmed-author:KotowiczMark... | lld:pubmed |
| pubmed-article:14753732 | pubmed:author | pubmed-author:HenryMargaret... | lld:pubmed |
| pubmed-article:14753732 | pubmed:author | pubmed-author:SandersKerrie... | lld:pubmed |
| pubmed-article:14753732 | pubmed:author | pubmed-author:SeemanEgoE | lld:pubmed |
| pubmed-article:14753732 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:14753732 | pubmed:volume | 19 | lld:pubmed |
| pubmed-article:14753732 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:14753732 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:14753732 | pubmed:pagination | 19-24 | lld:pubmed |
| pubmed-article:14753732 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:14753732 | pubmed:meshHeading | pubmed-meshheading:14753732... | lld:pubmed |
| pubmed-article:14753732 | pubmed:meshHeading | pubmed-meshheading:14753732... | lld:pubmed |
| pubmed-article:14753732 | pubmed:meshHeading | pubmed-meshheading:14753732... | lld:pubmed |
| pubmed-article:14753732 | pubmed:meshHeading | pubmed-meshheading:14753732... | lld:pubmed |
| pubmed-article:14753732 | pubmed:meshHeading | pubmed-meshheading:14753732... | lld:pubmed |
| pubmed-article:14753732 | pubmed:meshHeading | pubmed-meshheading:14753732... | lld:pubmed |
| pubmed-article:14753732 | pubmed:meshHeading | pubmed-meshheading:14753732... | lld:pubmed |
| pubmed-article:14753732 | pubmed:meshHeading | pubmed-meshheading:14753732... | lld:pubmed |
| pubmed-article:14753732 | pubmed:meshHeading | pubmed-meshheading:14753732... | lld:pubmed |
| pubmed-article:14753732 | pubmed:meshHeading | pubmed-meshheading:14753732... | lld:pubmed |
| pubmed-article:14753732 | pubmed:meshHeading | pubmed-meshheading:14753732... | lld:pubmed |
| pubmed-article:14753732 | pubmed:meshHeading | pubmed-meshheading:14753732... | lld:pubmed |
| pubmed-article:14753732 | pubmed:meshHeading | pubmed-meshheading:14753732... | lld:pubmed |
| pubmed-article:14753732 | pubmed:meshHeading | pubmed-meshheading:14753732... | lld:pubmed |
| pubmed-article:14753732 | pubmed:meshHeading | pubmed-meshheading:14753732... | lld:pubmed |
| pubmed-article:14753732 | pubmed:meshHeading | pubmed-meshheading:14753732... | lld:pubmed |
| pubmed-article:14753732 | pubmed:meshHeading | pubmed-meshheading:14753732... | lld:pubmed |
| pubmed-article:14753732 | pubmed:meshHeading | pubmed-meshheading:14753732... | lld:pubmed |
| pubmed-article:14753732 | pubmed:meshHeading | pubmed-meshheading:14753732... | lld:pubmed |
| pubmed-article:14753732 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:14753732 | pubmed:articleTitle | Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis Study. | lld:pubmed |
| pubmed-article:14753732 | pubmed:affiliation | Department of Clinical and Biomedical Sciences: Barwon Health, The University of Melbourne, Geelong, Australia. juliep@barwonhealth.org.au | lld:pubmed |
| pubmed-article:14753732 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:14753732 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14753732 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14753732 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14753732 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14753732 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14753732 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14753732 | lld:pubmed |
